Expression of pro- and anti-angiogenic isoforms of VEGF in the mouse model of oxygen-induced retinopathy

Experimental Eye Research

Volumn 93, Issue 6, 2011, Pages 921-926

  Zhao, Min ^a,b   Shi, Xuan ^a,b   Liang, Jianhong ^a,b   Miao, Yifei ^c,d   Xie, Wankun ^a,b   Zhang, Yan ^a,b   Li, Xiaoxin ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d Key Laboratory of Cardiovascular Science of the Ministry of Education   (China)

Author keywords

Neovascularization; Retinopathy of prematurity; VEGF; VEGFxxx; VEGFxxxb

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 164; VASCULOTROPIN 165B; VASCULOTROPIN A; VASCULOTROPIN XXX; VASCULOTROPIN XXXB;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLINDNESS; CARBOXY TERMINAL SEQUENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; RETROLENTAL FIBROPLASIA; VISUAL IMPAIRMENT;

AGE FACTORS; AGING; ALTERNATIVE SPLICING; ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; MICE; MICE, INBRED C57BL; OXYGEN; PROTEIN ISOFORMS; RETINA; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855917262     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.10.013     Document Type: Article

References (23)

1. Artac R.A., McFee R.M., Longfellow Smith R.A., Baltes-Breitwisch M.M., Clopton D.T., Cupp A.S. Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary. Biol. Reprod. 2009, 81:978-988.
2. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002, 62:4123-4131.
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
4. Cebe Suarez S., Pieren M., Cariolato L., et al. AVEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol. Life Sci. 2006, 63:2067-2077.
5. 165b) are elevated in experimental glaucoma. Mol. Vis. 2008, 14:1517-1524.
6. Ehlken C., Rennel E.S., Michels D., Grundel B., Pielen A., Junker B., Stahl A., Hansen L.L., Feltgen N., Agostini H.T., Martin G. Levels of VEGF but not VEGF165b are increased in the vitreous of patients with retinal vein occlusion. Am. J. Ophthalmol. 2011, 152:298-303. e291.
7. Harper S.J., Bates D.O. VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat. Rev. Cancer 2008, 8:880-887.
8. Kim I., Ryan A.M., Rohan R., Amano S., Agular S., Miller J.W., Adamis A.P. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest. Ophthalmol. Vis. Sci. 1999, 40:2115-2121.
9. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9-22.
10. Nowak D.G., Amin E.M., Rennel E.S., Hoareau-Aveilla C., Gammons M., Damodoran G., Hagiwara M., Harper S.J., Woolard J., Ladomery M.R., Bates D.O. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J.Biol. Chem. 2010, 285:5532-5540.
11. Ozaki H., Yu A.Y., Della N., Ozaki K., Luna J.D., Yamada H., Hackett S.F., Okamoto N., Zack D.J., Semenza G.L., Campochiaro P.A. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 1999, 40:182-189.
12. Perrin R.M., Konopatskaya O., Qiu Y., Harper S., Bates D.O., Churchill A.J. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005, 48:2422-2427.
13. 165b. FASEB J. 2008, 22:1104-1112.
14. 165b inhibits human tumour growth in mice. Br. J. Cancer 2008, 98:1250-1257.
15. Ricker L.J., Dieudonne S.C., Kessels A.G., Rennel E.S., Berendschot T.T., Hendrikse F., Kijlstra A., La Heij E.C. Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina 2011, 1-6.
16. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:833-835.
17. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
18. Terry T.L. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am. J. Ophthalmol. 1942, 25:203-204.
19. 165b, an anti-angiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and anti-angiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer 2008, 98:1366-1379.
20. Witmer A.N., Vrensen G.F., Van Noorden C.J., Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003, 22:1-29.
21. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, invivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004, 64:7822-7835.
22. Xu J., Dou T., Liu C., Fu M., Huang Y., Gu S., Zhou Y., Xie Y. The evolution of alternative splicing exons in vascular endothelial growth factor A. Gene 2011, 487:143-150.
23. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.